CELL TECHNOLOGY

The creation of Equa Health Life Ecosystem, with stem cell and immune cell technology as the core promotion, is committed to leading new changes in the life and health industry, innovating new industry technology standards, and promoting new processes in science and medicine; focusing on providing anti-aging and disease treatment Professional and high-quality integrated customized solutions, and continuous efforts to achieve a healthy and high-quality life for human beings

cell technology research

clinical application transformation

customized comprehensive health care

EQUA HEALTH International Center for Cell Therapy

EQUA HEALTH International Center for Cell Therapy located at The Hengqin Branch of Zhuhai People's Hospital, Hengqin Free Trade Zone, cooperated with Zhuhai People's hospital medical group in an innovative way, transformed the latest results of somatic cell immunotherapy on studies to clinical application, which truly brings hope for patients.

Led by a leading domestic and internationally renowned expert team of Professor Xia Jianchuan, an authority on immune cell therapy, Professor Zeng Zhenwu, a well-known immune cell therapy expert at Tokyo University School of Medicine, and Professor Lian Qizhou, a well-known expert on stem cell therapy at the University of Hong Kong
EQUA HEALTH International Center for Cell Therapy is an international advanced treatment platform, which has three components: clinical ward, cell culture laboratories for clinical application, and new researches laboratories.Adhering to the core values of "safety, quality, technology". Under the leadership of our chief scientist and expert in somatic immunotherapy, Professor Xia Jianchuan, we have a high-level expert team, which is a domestic first-class and internationally renowned cell therapy research platform. The center has a modern clinical application cell preparation room, advanced equipment and advanced cell quality testing methods, which provide a strong guarantee for the safe and effective application of somatic immunotherapy in the clinic.

The four most prominent advantages of EQUA HEALTH International Center::
The first is to have a mastery of the theoretical basis of somatic immunotherapy and the latest research results
Second: it has a medical team that has been working in the clinical front-line for a long time
Third: have a technical team skilled in somatic cell preparation
Fourth: It is a research team with continuous development of new projects for somatic cell therapy

Chief Scientific Officer Jianchuan Xia Ph.D.

Graduated from Harbin Medical University in 1998 with a doctor of medicine; from 1998 to 2000, he worked as a postdoctoral researcher in oncology at the Affiliated Tumor Hospital of Sun Yat-sen University; from 2000 to 2003, he was engaged in tumor immunotherapy and oncology at Harvard University Dana-Farber Cancer Institute Vaccine research. Chief Scientist of National Key R&D Project, Director of Biotherapy Center, Sun Yat-sen University Tumor Hospital, Director of Somatic Cell Therapy and Health Research Center, Director of Asia Pacific Society of Medical Bioimmunology, Director of China Cell Therapy Quality Control and Research Professional Committee, China Biotherapy Vice Chairman of the Professional Committee of Clinical Application, Executive Director of China Medical Biotechnology Association, Executive Director of China Cell Society, Chairman of Guangdong Society of Cell Biology, Chairman of Biotherapy Professional Committee of Guangdong Anti-Cancer Association, National Food and Drug Administration New drug review expert, leader of the immune and genetic research group of the National Key Laboratory of Oncology in South China

The breakthrough results of immune cells can be seen:
It is the first to prove that DC/tumor fusion cell vaccine can induce spontaneous breast cancer transgenic mice to produce an anti-tumor immune response, laying the foundation for the application of DC/tumor fusion cell vaccine in the clinical treatment of tumors. The research results were published in the American Journal of Immunology (The Journal of Immunology 2003 and 2004). It is the first in China to establish the operating specifications for the preparation of tumor somatic cells, the safety testing standards for the clinical application of tumor somatic cells, and the clinical application specifications for somatic immunotherapy, and formulated the first "autoimmune cell (T cell, NK cell) treatment technology for my country" Standardized management" has made important contributions to the clinical application of cellular immunotherapy in China on a standardized basis